1 **Original Resarch Article** Distinguishing non severe cases of dengue from COVID-19 in the context of co-2 epidemics: a cohort study in a SARS-CoV-2 testing center on Reunion island 3 4 Antoine Joubert,^{1†} Fanny Andry,^{1,2,3†} Antoine Bertolotti,^{1,2,4} Frédéric Accot,¹ Yatrika 5 Koumar,^{1,2,3} Florian Legrand,^{1,3} Patrice Poubeau,^{1,2,3} Rodolphe Managuin,^{1,2,3} Patrick 6 Gérardin,^{4‡*} Cécile Levin,^{1,2,3‡*} 7 8 ¹ COVID-19 testing centre, Centre Hospitalier Universitaire de la Réunion, Saint Pierre, Reunion, 9 10 France ² Department of Infectious Diseases and Tropical Medicine, Centre Hospitalier Universitaire de la 11 12 Réunion, Saint Pierre, Reunion, France 3 City to Hospital Outpatient Clinic for the care of COVID-19, Centre Hospitalier Universitaire de la 13 14 Réunion, Saint Pierre, Reunion, France ⁴ Centre for Clinical Investigation – Clinical Epidemiology (CIC 1410), Institut National de la Santé et 15 de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de la Réunion, Saint Pierre, 16 17 Reunion, France 18 Short running head title: Dengue and COVID-19 in co-epidemics 19 ^{**} Contributed equally 20 * Correspondence: P. Gérardin, Center for Clinical Investigation (CIC1410), CHU Réunion, BP 21 350, 97448 Saint-Pierre Cedex – Reunion, France (patrick.gerardin@chu-reunion.fr); C. Levin, 22 23 Department of Infectious Diseases and Tropical Medicine, CHU Réunion, BP 350, 97448 24 Saint-Pierre Cedex – Reunion, France (cecile.levin@chu-reunion.fr) 25 26 40-word summary of the article's main point 27 In the COVID-19 dengue co-epidemic setting of Reunion island, dengue was found more symptomatic than COVID-19 and associated with body ache, headache and retro-orbital 28 29 pain, while COVID-19 was found associated with contact, anosmia, delayed presentation and absence of active smoking. 30

31 Abstract

32 **Background.** As coronavirus (COVID-19) is spreading globally, several countries are handling 33 dengue epidemics. As both infections are deemed to share similarities at presentation, it 34 would be useful to distinguish COVID-19 from dengue in the context of co-epidemics. In this 35 aim, we performed a cohort study to identify predictors of both infections. Methods. All the subjects suspected of COVID-19 between March 23 and May 10, 2020, 36 37 were screened for COVID-19 within the testing center of the University hospital of Saint-38 Pierre, Reunion island. The screening consisted in a questionnaire surveyed in face-to-face, a 39 nasopharyngeal swab specimen for the Severe Acute Respiratory Syndrome Coronavirus-2 40 (SARS-CoV-2) reverse transcription polymerase chain-reaction and a rapid diagnostic orientation test for dengue. Factors independently associated with COVID-19 or with dengue 41

42 were sought using multinomial logistic regression models, taking other febrile illnesses (OFIs)

43 as controls.

Results. Over a two-month study period, we identified among 80 COVID-19, 60 non-severe
dengue and 872 OFIs cases, delayed presentation (>3 days) since symptom onset (Odds ratio
1.89, 95% confidence interval 1.4-3.40), contact with a COVID-19 positive case (OR 3.81,
95%CI 2.12-6.82) and anosmia (OR 8.27, 95%CI 4.39-15.54) as independent predictors of
COVID-19, body ache (OR 6.83, 95%CI 2.84-16.41), headache (OR 5.38, 95%CI 1.81-15.94)
and retro-orbital pain (OR 7.45, 95%CI 3.17-17.50) as independent predictors of dengue,
while smoking was less likely observed with COVID-19 (OR 0.27, 95%CI 0.10-0.74).

Conclusions. Although prone to potential biases, these data suggest that non-severe dengue
may be more symptomatic than COVID-19 in a co-epidemic setting with higher dengue
attack rates.

54 **Keywords** : coronavirus, COVID-19, dengue, risk factors, cohort study

55 Background

During the past decades, there have been growing concerns about the risks of overlapping epidemics and co-infections with emergent viruses, especially with arboviruses that can share the same *Aedes* mosquito vector [1,2]. Yet, surprisingly, since the 2009 flu pandemic, the differential diagnosis between influenza and dengue has been scarcely investigated [3].

As Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is spreading globally, several countries are handling dengue epidemics, with fear for their healthcare systems and most vulnerable populations [4]. Thus, differentiate between the two diagnoses may be challenging and lead to misdiagnosis, which may occasion both delays in treatment and preventable deaths, but also inadequate isolation measures with the potential to trigger outbreaks, especially in the healthcare setting [4].

On Reunion island, a French overseas department located in the Indian ocean, best known to have host one of the largest chikungunya outbreaks and harbor a highly comorbid population [5,6], dengue virus (DENV) is circulating since 2004 under an endemo-epidemic pattern with outbreaks usually peaking between March and May, and increases with yearly upsurges since 2015 [7]. In 2020, the first cases of coronavirus 2019 (COVID-19) were detected on the island by March 11, six days before the French authorities decree the lockdown.

In this context, a new case of COVID-19 and dengue co-infection was reported [8]. Anticipating that the differential diagnosis between the two infections would be challenging, we designated a retrospective cohort study aimed at identifying the clinical and epidemiological profiles of SARS-CoV-2 and DENV infections to guide their management and mitigate the impact of COVID-19 pandemic surge on the island.

78 Methods

79 The full details of the methods can be found in the Supplementary Methodological appendix.

80 Study design and setting

81 We conducted a retrospective cohort study between March 23 and May 10, 2020, on all subjects screened for the CO-VID-19 within the UDACS (Unité de Dépistage Ambulatoire du 82 83 COVID-19 Sud) of Saint-Pierre, one of the two SARS-CoV-2 testing centers of the Centre 84 Hospitalier Universitaire Réunion (CHU). When SARS-CoV-2 emerged on the island, the 85 dengue epidemic was already burgeoning, the UDACS was placed in the second line of the reception system for COVID-19 patients, the frontline being the emergency units and the 86 dedicated hospital for COVID-19 patients, the CHU Félix Guyon, located in Saint-Denis, 87 88 whereby are the prefecture and the international airport.

89 **Ethics statement**

90 Outpatients presenting consecutively at the SARS-CoV-2 testing center were informed of the study orally and by means of an information sheet. People who expressed no opposition 91 were asked to answer a questionnaire and surveyed in face-to-face by a nurse, in accordance 92 to the French legislation on bioethics for retrospective researches. Patient's medical records 93 were retrospectively reviewed, and de-identified data were collected in standardized forms 94 95 according the MR-004 procedure of the Commission Nationale de l'Informatique et des 96 *Libertés* (the French information protection commission). The ethical character of this study on previously collected data was approved by the Scientific Committee for COVID-19 97 98 research of the CHU Réunion and de-identified data were registered on the Health Data Hub.

99 Data collection

The items of the questionnaire included information on demographics, occupation, risk
 factors, comorbidities, intra-household and individual exposure to SARS-CoV-2, individual

symptoms and treatment. Temperature, pulse rate, respiratory rate and oxygen saturation

103 (SpO₂) were measured upon the consultation, as well as the presence of cough and anxiety.

104 **Diagnostic procedures**

105 All the attendees were screened for SARS-CoV-2 using a nasopharyngeal swab inserted and 106 held in one nostril for about twenty seconds [9]. The sample was processed for a SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) using the Allplex 2019-nCov[™] 107 108 assay (Seegene, Seoul, Republic of Korea) or an in-house kit (CNR Pasteur), targeting N, RdRP 109 and E genes, or N and IP2/IP4 targets of RdRP, respectively. In addition, each patient suspected of dengue was tested for NS1 antigen using an OnSite[™] Duo dengue Ag-lgG-lgM 110 111 rapid diagnostic test (CTK Biotech, San Diego, CA, USA) and if negative further explored with a DENV RT-PCR or a dengue serology according to the timing of symptoms. People without 112 113 symptoms were excluded from the study. Patients requiring hospitalization were transferred 114 promptly from the UDACS to the COVID-19 units.

115 Statistical analysis

116 Given the research purpose, co-infections at clinical presentation were excluded from the 117 analysis. Proportions between non COVID-19 and non-dengue other febrile illnesses (OFIs), COVID-19 and dengue subjects were compared using Chi square or Fisher exact tests, as 118 119 appropriate. Univariable and multivariable multinomial logistic regression models were 120 fitted within Stata14[®] (College Station, Texas, USA) to identify independent predictors of COVID-19 and dengue, taking OFIs as controls. For all these analyses, observations with 121 122 missing data were ruled out and a P-value less than 0.05 was considered as statistically 123 significant.

124 **Results**

125	Between March 23 and May 10, 2020, 1,715 subjects presented at the UDACS for screening
126	or diagnosis purposes. Of these, 370 incoming patients were screened opportunistically for
127	COVID-19 as part of an expanded screening week targeting admissions to our hospital (75%
128	asymptomatic, all tested negative), and 332 were fully asymptomatic subjects (46% with the
129	notion of a COVID-19 contact, 23% health care workers, all tested negative). Both of these
130	populations were excluded from the study, leaving 1,013 outpatients eligible to the analysis.
131	The study population is shown in Figure 1.
132	The hospitalization rates for the COVID-19 and dengue patients were higher than those
133	observed for the patients affected by OFIs (16.7% and 13.1%, respectively versus 1.8%, P
134	<0.001). Among 40 inpatients, 2 patients out of 22 met the criteria for COVID-19 pneumonia
135	and 6 out of 8 had dengue warning signs but none severe dengue at clinical presentation. No
136	COVID-19 dengue co-infection was observed at clinical presentation.
137	COVID-19 patients presented later in their evolution compared to the subjects affected
138	by dengue or OFIs (time elapsed since symptom onset, 7.5 days <i>versus</i> 4.2 days or 6.3 days,
139	P<0.001). The average levels of temperature, pulse rate, respiratory rate and spO2 did not
140	differ between the three groups of patients.
141	Univariable analysis proposed contact with a COVID-19+ case, recent return from
142	travel abroad (<15 d), fever, ageusia, anosmia (loss of smell) and delayed presentation (>3 d)

since symptom onset as candidate predictors for COVID-19, active smoking as candidate protective factor against COVID-19, previous episode of dengue, fever, body ache (*i.e.*, muscle pain, backache with tightness/stiffness), ageusia, gut symptoms (*i.e.*, nausea, vomiting, dyspepsia, eructation or abdominal pain), metallic taste, fatigue, headache and retro-orbital pain as candidate predictors for dengue, and upper respiratory tract infection

(URTI) symptoms (*i.e.*, sore throat, runny nose, nasal congestion or sneezing) as a candidate
 protective factor for both diagnoses referring to another cause of febrile illness
 (Supplementary Table 1).

Multivariable analysis identified delayed presentation (>3 d) since symptoms onset, contact with a COVID-19 positive case and anosmia as independent predictors of COVID-19, body ache, headache and retro-orbital pain as independent predictors of dengue, while active smoking was less likely observed with COVID-19 and URTI symptoms were indicative of OFIs (Table 1).

A sensitivity analysis restricted to the patients with COVID-19 or with dengue confirmed anosmia, URTI symptoms and delayed presentation (>3 d) on the one hand, body ache, fatigue, headache, retro-orbital pain and rapid presentation (\leq 3 d) on the other hand, as discriminating factors between the two infections (Supplementary Table 2).

160 **Discussion**

COVID-19 and dengue are two clinically similar entities, especially within the first 24 to 48 161 hours from symptom onset [10]. In a context of co-epidemics, our cohort study, conducted 162 163 within a SARS-CoV-2 testing center upon mild to moderate cases of COVID-19 and nonsevere cases of dengue identified several key distinctive features for both infections. Thus, 164 among the clinically discriminant variables at presentation, retro-orbital pain, body ache and 165 166 headache were strong predictors of dengue while anosmia was the only predictor of COVID-167 19 and URTI symptoms were indicative of OFIs. To a lesser extent, gut symptoms other than diarrhea, dysgeusia and fatigue were suggestive of dengue whereas cough referred to 168 another diagnosis (OFIs or COVID-19), albeit found in nearly a third of dengue. Thus, among 169 170 the epidemiological variables, the contact with a COVID+ case and a delayed presentation 171 beyond three days of symptom onset were predictive of COVID-19, a rapid presentation 172 within three days was suggestive of dengue, while active smoking was less likely observed with COVID-19 or associated with OFIs. These elements are summarized in the Supplemental 173 174 Figure 1.

Our findings reveal several unexpected differences at the presentation to hospital between COVID-19 or dengue as compared to OFIs, and between COVID-19 and dengue, dengue appearing at first glance more symptomatic and with a more abrupt onset than COVID-19 or OFis in the setting of a SARS-CoV-2 testing center.

These discrepancies might reflect first a selection bias, the more symptomatic cases of both infections having been referred primarily to the emergency units, these redirecting the COVID-19 cases towards the Saint-Denis referral hospital for quarantine purpose. This could be arguably deduced from weighing on the inverse probability of hospitalization, which was on average 2.5-fold higher than from the UDACS, all through the study period.

Doing so abrogates, for instances, the effects of a delayed presentation and the protection 184 of active smoking for the prediction of COVID-19 (data not shown). Together with the fact 185 186 that the dengue epidemic was more active in the south, this fuels the idea that time to 187 presentation in our study partly stemmed from differences in recruitment driven both by the 188 organization and access to care. Importantly, weighing the analysis strengthened also the odds ratios of a contact with a COVID-19+ case for the same, as well as those of headache 189 190 and retro-orbital pain for the prediction of dengue. These elements suggest that this 191 putative selection bias was more pronounced on epidemiological than on clinical variables.

Second, our results might also be affected by a misclassification bias, which may arise from the poor sensitivity of both rapid NS1 antigen and SARS-CoV-2 RT-PCR. Consistent with this, are the high percentages of cough and URTI symptoms in dengue cases, for instances.

195 This being said, our findings are also in agreement with the literature.

196 First, the fact that dengue was more symptomatic than COVID-19 fulfills both the concept of "force infection" and the trade-off model according to which, the time spent in 197 198 the susceptible group of an infectious disease is inversely correlated to its incidence [11], 199 and the virulence (e.g., ability to cause illness, lethality) grows with the transmission rate 200 until it reaches a plateau [12]. Consistent with these assumptions, according to Santé 201 Publique France reports, the attack rate observed over the study period was 22-fold higher 202 for dengue (\approx 905 per 100.000 inhabitants) than for COVID-19 (\approx 41 per 100.000 inhabitants). 203 This was explained by the recent introduction of DENV-1 serotype (March 2019) 204 complicating five years of DENV-2 circulation [7], cases of secondary dengue, the 205 effectiveness of the lockdown to slow the progression of COVID-19 and the fact that SARS-CoV-2 impacted at that time mainly "healthy" individuals (travelers and their relatives). In 206 207 this framework, the relevance of body ache, headache and retro-orbital pain at presentation

for the differential diagnosis between COVID-19 and dengue accounts for the involvement of dengue in the general and digestive spheres, as proposed by Nacher et *al.* in a recent opinion paper, COVID-19 being more pronounced in the respiratory sphere [10]. Interestingly, we also found one COVID-19+ case who was tested negative for dengue suffering retro-orbital pain, as previously reported in Taiwan [13].

Second, our cohort study supports the high positive predictive values and specificities of the contact with a COVID-19+ case and anosmia for the diagnostic of COVID-19, which is congruent with risk prediction models developed for healthcare workers in Italy [14] and findings from the *Coranosmia* cohort study in France [15], respectively.

217 Together with the abovementioned putative selection bias, the delayed presentation 218 to hospital of COVID-19 cases, as compared to dengue, might also illustrate the mild ("pauci-219 symptomatic") character of COVID-19 illness during the first pandemic surge on Reunion 220 island, as well as some consecutive lags in contact tracing. Overall, individuals who did not 221 feel or only slightly sick with COVID-19 might have not feel the need to be tested. However, 222 this hypothesis does not stand the absence of clear association between the proportions of 223 asymptomatic infections and time to presentation (*i.e.*, with 3-fold more asymptomatic 224 cases, OFIs cases presented faster than COVID-19 cases; data not shown).

Interestingly, active smoking was less likely observed with COVID-19 as compared to OFis or dengue, but this effect was not robust as suggested above. Moreover, it was not replicated for asymptomatic SARS-CoV-2 infections, nor it was among COVID-19+ cases for the protection against illness (data not shown). Notwithstanding, this result fuels the smoker's paradox according to which active smokers were underreported among the patients hospitalized for COVID-19 in several countries [16].

231	In conclusion, our cohort study identified several factors distinguishing non severe
232	dengue from COVID-19 at clinical presentation in a context of recent dengue endemicity and
233	first introduction of SARS-CoV-2. Although prone to potential biases, these data suggest that
234	non severe dengue may be more symptomatic than COVID-19 in a co-epidemic setting with
235	higher dengue attack rates. Whether the findings could serve other regions facing co-
236	epidemics requires more investigations and development of more accurate diagnostic tools.

237

238 Acknowledgments

The authors are indebted to the staffs of the department of Infectious Disease and Tropical Medicine and the SARS-CoV-2 testing center, especially the nurses who performed the survey. They thank the biologists of the CHU for timely diagnosis and the attendees for kind interest in research.

243

244 Supplementary data

Supplementary materials are available at *Clinical Infectious Diseas*es online. While the supplementary tables have been copyedited, the Methodological appendix and the Venn diagram have not been copyedited and are the sole responsibility of the authors. Questions and comments about these should be addressed to the corresponding author.

250

251	Author's contributions.	F.A and	CL conceived	and designed	the .	study.	A.J,	F.A,	А.В,	F.A,	Υ. <i>Κ</i>	,
-----	-------------------------	---------	--------------	--------------	-------	--------	------	------	------	------	-------------	---

- 252 F.L, P.P, R.M contributed to the data acquisition. P.G designed and performed the statistical
- 253 analyses and is the data curator. F.A, C.L., A.B., and PG interpreted the data. A.J. and C.L.
- 254 drafted the paper with the help of P.G. All authors contributed to critical examination of the
- 255 paper for intellectual content and approved the final manuscript.

256

- 257 List of abbreviations. CIR: cumulative incidence rate (= attack rate); CNR: centre national de
- 258 reference; COVID-19: coronavirus 2019; DENV: dengue virus; OFIs: other febrile illnesses;
- 259 aOR: adjusted odds ratio; RT-PCR: reverse transcription polymerase chain reaction; SARS-
- 260 CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2; spO2: partial saturation of oxygen;
- 261 UDACS: unite de dépistage ambulatoire du coronavirus sud; URTI : upper respiratory tract
- 262 infection; 95% CI: 95% confidence intervals.

263

264 Funding. None

265

266 Potential conflicts of interest. All the authors: No reported conflicts. All authors have signed
267 the ICMJE form disclosure of potential conflicts of interest.

References 268

- Caron M, Paupy C, Grard G, Becquart P, Mombo I, Nso BB, et al. Recent introduction and 269 1
- 270 rapid dissemination of Chikungunya virus and Dengue virus serotype 2 associated with
- 271 human and mosquito coinfections in Gabon, central Africa. Clin Infect Dis 2012; 55: e45-
- 272 53. http://dx.doi:10.1093/cid/cis530. Epub 2012 Jun 5.
- 273 2 Waggoner JJ, Gresh L, Vargas MJ, Ballesteros G, Tellez Y, Soda J, et al. Viremia and clinical 274 presentation in Nicaraguan patients infected with Zika virus, Chikungunya virus and 275
- Dengue virus. Clin Infect Dis 2016; 63:1584-90. http://dx.doi:10.1093/cid/ciw589.
- 276 Huang SY, Lee IK, Wang L, Liu JW, Hung SC, Chen CC, et al. Use of simple clinical and 3.
- 277 laboratory predictors to differentiate influenza from dengue and other febrile illnesses in
- 278 the emergency room. BMC Infect Dis 2014; 14: 623 . http://dx.doi:10.1186/s12879-014-
- 279 0623-z.
- Wilder-Smith A, Tissera H, Ooi EE, Coloma J, Scott TW, Gubler DJ. Preventing dengue 280 4. epidemics during COVID-19 pandemic. Am J Trop Med Hyg 2020; 103: 570-1. 281 282 http://dx.doi: 10.4269/ajtmh.20-0480.
- 283 Gérardin P, Guernier V, Perrau J, Fianu A, Le Roux K, Grivard P, et al. Estimating 5. 284 Chikungunya prevalence in La Réunion island outbreak by serosurveys: two methods for 285 two critical times of the epidemic BMC Infect Dis 2008; 8: 99. http://dx.doi:10.1186/1471-286 2334-8-99.
- Cournot M, Lenclume M, Le Moullec N, Debussche C, Doussiet E, Fagot-Campagna A, et 287 6. 288 al. Prevalence, treatment and control of hypertension in La Réunion: the RÉDIA 289 population-based cohort study. Blood Press 2017; 26(1):39-47. http://dx.doi: 290 10.1080/08037051.2016.1182854. Epub 2016 May 19.

- 291 7. Vincent M, Larrieu S, Vilain P, Etienne A, Solet JL, François C, et al. From the threat to the
- large outbreak: dengue on Reunion island. Euro Surveill 2019; 24: 1900346. http://dx.doi:
- 293 10.2807/1560-7917.ES.2019.24.47.1900346.
- 8. Verduyn M, Allou N, Gazaille V, Andre M, Desroche T, Jaffar M-C, et al. Co-infection of
- 295 dengue and COVID-19: A case report. PLoS Negl Trop Dis 2020; 14: e0008476.
- 296 https://dx.doi.org/10.1371/journal.pntd.0008476.
- Marty FM, Chen K, Verrill KA. How to obtain a nasopharyngeal swab specimen. New Engl
 J Med 2020; 382; e76. https://dx.doi/10.1056/NEJMvcm2010260.
- 10. Nacher M, Douine M, Gaillet M, Flamand C, Rousset D, Rousseau C, et al. Simultaneous
- dengue and COVID-19 epidemics: difficult days ahead? PLoS Negl Trop Dis 2020; 14:
- 301 e0008426. https://dx.doi.org/10.1371/journal.pntd.0008426.
- 302 11. Katzelnick LC, Ben-Shachar R, Mercado JC, Rodriguez-Barraguer I, Elizondo D, Arguello S,
- 303 et al. Dynamics and determinants of the force of infection of dengue virus from 1994 to
- 304 2015 in Managua, Nicaragua. Proc Natl Acad Sci U S A 2018; 115: 10762-7.
- 305 https://dx.doi.org/10.1073/pnas.1809253115.
- 306 12. Ebert D, Bull JJ. Challenging the trade-off model for the evolution of virulence: is
 307 virulence management feasible? Trends Microbiol 2013; 11: 15-20.
 308 https://dx.doi.org/10.1016/s0966-842x(02)00003-3.
- 309 13. Ruy W, Hsu SY, Tsai HL, CT Chen. COVID-19 mimicking dengue fever with the initial
- 310 manifestation of retro-orbital pain a rare case. J Formos Med Assoc 2020 Jun 4; S0929-
- 311 6646(20)30229-1.https://dx.doi.org/10.1016/j.jfma.2020.05.039. Online ahead of print.
- 14. Ng MY, Wan EYF, Wong HYF, Leung ST, Lee JCY, Chin TW, et al. Development and
 validation of risk prediction models for COVID-19 positivity in a hospital setting. Int J

- 314
 Infect
 Dis
 2020
 Sep
 15;
 S1201-9712(20)30738-4.
- 315 https://dx.doi.org/10.1016/j.ijid.2020.09.022. Online ahead of print.
- 316 15. Salmeron Ceron D, Bartier S, Hautefort C, Nguyen Y, Nevoux J, Hamel AL, et al. Self-
- 317 reported loss of smell with nasal obstruction to identify COVID-19. The multicenter
- 318 Coranosmia cohort study. J Infect 2020; 81: 614-20.
- 319 https://dx.doi.org/20.1016.j.jinf.2020.07.005.
- 320 16. Usman MS, Siddiqi TJ, Khan MS, Patel UK, Shahid I, Ahmed J, et al. Is there a smoker's
- 321 paradox in COVID-19? BMJ Evid Based Med. 2020 Aug 11:bmjebm-2020-111492.
- 322 https://dx.doi/10.1136/bmjebm-2020-111492. Online ahead of print.

Outcomes (versus other febrile illnesses as controls	5*]	COVID-19 (n = 74)				Dengue (n = 60)					
Predictors	n	CIR, %	aOR	95% CI	<i>P</i> value	n	CIR, %	aOR	95% CI	<i>P</i> value	
Age, years											
0-30 (Q1)	24	8.63	0.90	0.41 - 1.93	0.782	8	2.88	0.21	0.06 - 0.68	0.009	
31-41 (Q2)	10	3.68	0.41	0.17 - 1.00	0.050	25	9.19	1.03	0.43 - 2.44	0.947	
42-54 (Q3)	26	10.20	1.24	0.60 - 2.53	0.554	13	5.10	0.38	0.14 - 0.99	0.048	
55-94 (Q4)	14	8.38	1			14	8.38	1			
Contact with a COVID-19 positive case	40	15.33	3.81	2.12 - 6.82	< 0.001	6	2.30	0.88	0.34 - 2.24	0.778	
Active smoking ⁺	4	2.53	0.27	0.10 - 0.74	0.011	12	7.59	1.72	0.34 - 2.24	0.182	
Cough	32	6.82	0.81	0.45 - 1.44	0.471	17	3.62	0.38	0.20 - 0.74	0.004	
Body ache [‡]	29	7.09	1.12	0.62 - 2.01	0.705	52	12.71	6.83	2.84 - 16.41	< 0.001	
Anosmia	26	27.96	8.27	4.39 - 15.54	< 0.001	3	3.23	0.43	0.09 - 2.07	0.296	
Headache	28	5.69	0.84	0.50 - 1.41	0.508	55	11.18	5.38	1.81 - 15.94	0.002	
Retro-orbital pain	1	2.27	0.39	0.03 - 4.19	0.437	17	38.64	7.45	3.17 - 17.50	< 0.001	
URTI symptoms [#]	28	5.63	0.53	0.31 - 0.89	0.017	20	4.02	0.46	0.23 - 0.91	0.027	
Presentation > 3 days after symptom onset	54	9.69	1.89	1.04 - 3.40	0.035	24	4.31	0.76	0.40 - 1.44	0.402	

Table 1. Independent predictors in multivariate analysis distinguishing COVID-19 and dengue from other febrile illnesses among 972 subjects consulting a COVID-19 screening center during the COVID-19 dengue co-epidemics, Reunion island, Saint-Pierre, March 23-May 10, 2020

Multinomial logistic regression model with other non COVID-19 non dengue febrile illnesses*, taken as controls. Data are numbers, cumulative incidence rates (CIR) expressed as percentages, adjusted odd ratios (aOR), 95% confidence intervals (95% CI) and *P* values for Wald tests. † Current smokers, as compared to never smokers and past smokers ‡ muscle pain or backache with tightness and/or stiffness; [#] sore throat, runny nose, nasal congestion, or sneezing. The indicators of performance of the model

are as follows: Bayesian information criterion -5696, Goodness of fit chi-2 test's probability 0.605, areas under the receiver operating curves 0.795 and 0.892, respectively.

23 Figures

24 Figure 1. Study population

